{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:06:00Z","timestamp":1790078760224,"version":"4.0.1"},"reference-count":67,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic review (2019\u20132025) synthesizes research results regarding the efficacy and safety of dienogest (DNG) and GnRH antagonists, while also summarizing research on new directions in endometriosis treatment. Methods: Following PRISMA 2020 guidelines, we searched Medline for clinical evidence on established standards and emerging therapies. A structured narrative synthesis was performed. Quality was assessed using Cochrane RoB 2 and ROBINS-I tools. Results: A total of 44 out of 926 records were analyzed. The review confirms the efficacy of DNG as a first-line treatment for endometriosis. Relugolix combination therapy appears to be a more effective and safer option than elagolix or relugolix monotherapy in reducing dysmenorrhea and pelvic pain. Research concerning immunotherapy for endometriosis (using tocilizumab, anakinra, bevacizumab, and anti-CD47 antibodies) is subject to a high risk of bias and very low GRADE certainty. Nevertheless, these findings may serve as a foundation for further studies, which are necessary to evaluate their efficacy and safety in the treatment of endometriosis. Conclusions: DNG is generally well-tolerated, but further studies are needed to unequivocally determine the impact of DNG on BMD loss and cancer risk. Research on GnRH antagonists indicates their increasing role in the future management of endometriosis. There are new perspectives in endometriosis pharmacotherapy\u2014including immunotherapy; however, there is a fundamental need for their further development and evaluation.<\/jats:p>","DOI":"10.3390\/jcm15187238","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:09:35Z","timestamp":1790075375000},"page":"7238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3977-3649","authenticated-orcid":false,"given":"Zuzanna","family":"Betiuk","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4181-7967","authenticated-orcid":false,"given":"Martyna","family":"B\u0142a\u017cyca","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6453-9838","authenticated-orcid":false,"given":"Martyna","family":"Bartoszczyk","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6665-8931","authenticated-orcid":false,"given":"Katarzyna","family":"Kuty\u0142a","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8136-9997","authenticated-orcid":false,"given":"Natalia","family":"Gierulska","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Tarkowski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16 St., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Ku\u0142ak","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16 St., 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023). Fact Sheets: Endometriosis, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"hoab029","DOI":"10.1093\/hropen\/hoab029","article-title":"An international terminology for endometriosis, 2021","volume":"2021","author":"Tomassetti","year":"2021","journal-title":"Hum. Reprod. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","article-title":"ESHRE guideline: Endometriosis","volume":"2022","author":"Becker","year":"2022","journal-title":"Hum. Reprod. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103030","DOI":"10.1016\/j.eclinm.2024.103030","article-title":"Hospitalisations and length of stays in women with endometriosis: A data linkage prospective cohort study","volume":"80","author":"Gete","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12701\/yujm.2020.00444","article-title":"Classification of endometriosis","volume":"38","author":"Lee","year":"2021","journal-title":"J. Yeungnam Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ca.24059","article-title":"The implications of the anatomy of the nerves and vessels in the treatment of rectosigmoid endometriosis","volume":"37","author":"Centini","year":"2024","journal-title":"Clin. Anat."},{"key":"ref_7","first-page":"e1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3349\/ymj.2024.0518","article-title":"Gene Expression Profiling and Pathway Analysis of the Effect of Dienogest on Ovarian Endometriosis","volume":"66","author":"Chung","year":"2025","journal-title":"Yonsei Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.34172\/aim.2021.96","article-title":"Comparing the Effect of Dienogest and OCPs on Pain and Quality of Life in Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"24","author":"Niakan","year":"2021","journal-title":"Arch. Iran. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e38525","DOI":"10.1097\/MD.0000000000038585","article-title":"Comparison of dienogest or combinations with ethinylestradiol\/estradiol valerate on the pain score of women with endometriosis: A prospective cohort study","volume":"103","author":"Yurtkal","year":"2024","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Caruso, S., Cianci, A., Iraci Sareri, M., Panella, M., Caruso, G., and Cianci, S. (2022). Randomized study on the effectiveness of nomegestrol acetate plus 17\u03b2-estradiol oral contraceptive versus dienogest oral pill in women with suspected endometriosis-associated chronic pelvic pain. BMC Women\u2019s Health, 22.","DOI":"10.1186\/s12905-022-01737-7"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ma, Y., Wang, W.X., and Zhao, Y. (2024). Dienogest in conjunction with GnRH-a for postoperative management of endometriosis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1373582"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Atlihan, U., Yavuz, O., Ata, C., Avsar, H.A., and Erkilinc, S. (2025). Effects of dienogest treatment on endometrioma-related clinical symptoms and endometrioma size: Retrospective cohort study. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1581661"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2336121","DOI":"10.1080\/09513590.2024.2336121","article-title":"Long-term treatment for endometriosis with dienogest: Efficacy, side effects and tolerability","volume":"40","author":"Vannuccini","year":"2024","journal-title":"Gynecol. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114540","DOI":"10.1016\/j.ejogrb.2025.114540","article-title":"Association between depressive symptoms and dienogest in patients treated for endometriosis","volume":"312","author":"Park","year":"2025","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"dead093.678","DOI":"10.1093\/humrep\/dead093.678","article-title":"Change of bone mineral density after long-term use of dienogest with calcium and vitamin D supplementation after surgical treatment of endometrioma","volume":"38","author":"Park","year":"2023","journal-title":"Hum. Reprod."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1007\/s43032-020-00453-7","article-title":"The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of Endometrioma","volume":"28","author":"Kim","year":"2021","journal-title":"Reprod. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ijgo.70424","article-title":"Dienogest use and the risk of breast and gynecologic cancers: A nationwide population-based study","volume":"172","author":"Jhang","year":"2026","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous Thromboembolic Risk of Estradiol Valerate\u2013Dienogest Compared with Ethinyl Estradiol\u2013Levonorgestrel Combined Oral Contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.rbmo.2020.07.022","article-title":"Pretreatment with dienogest in women with endometriosis undergoing IVF after a previous failed cycle","volume":"41","author":"Barra","year":"2020","journal-title":"Reprod. Biomed. Online"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13048-019-0597-y","article-title":"The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosis","volume":"12","author":"Tamura","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_22","unstructured":"U.S. Food and Drug Administration (2025, October 26). Highlights of Prescribing Information: Orilissa (Elagolix) Tablets, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66&type=display."},{"key":"ref_23","unstructured":"U.S. Food and Drug Administration (2022). Myfembree Drug Label."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: Two replicate phase 3 studies","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum. Reprod."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose\u2013response manner: A randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil. Steril."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Osuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., and Terakawa, N. (2021). Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, in women with endometriosis-associated pain: Phase 2 safety and efficacy 24-week results. BMC Women\u2019s Health, 21.","DOI":"10.1186\/s12905-021-01393-3"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1\u2013e630-630.e13","DOI":"10.1016\/j.ajog.2024.06.040","article-title":"Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: Twelve months of an ongoing randomized phase 3 trial","volume":"231","author":"Miller","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.AOG.0000929852.03048.10","article-title":"Long-Term Safety of Elagolix with Add-Back in Women with Endometriosis-Associated Pain: 36-Month Results","volume":"141","author":"Simon","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.fertnstert.2024.07.011","article-title":"Efficacy and safety of the combination of estetrol 15 mg\/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: A multicenter, placebo-controlled, double-blind, randomized study","volume":"122","author":"Harada","year":"2024","journal-title":"Fertil. Steril."},{"key":"ref_33","unstructured":"(2024, December 03). Estetrol\/Drospirenone to Reduce the Average Size of Endometriomas. ClinicalTrials.gov NCT05837624, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05837624."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10760296241286514","DOI":"10.1177\/10760296241286514","article-title":"Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis","volume":"30","author":"Kobayashi","year":"2024","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ptr.8037","article-title":"Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure, and oxidative stress in polycystic ovary syndrome patients: A triple-blind randomized clinical trial","volume":"38","author":"Jabarpour","year":"2024","journal-title":"Phytother. Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rostami, S., Alyasin, A., Saedi, M., Nekoonam, S., Khodarahmian, M., Moeini, A., and Amidi, F. (2023). Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical trial. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1144323"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13048-024-01537-7","article-title":"Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: A randomized clinical trial","volume":"17","author":"Shafie","year":"2024","journal-title":"J. Ovarian Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e18464","DOI":"10.1111\/jcmm.18464","article-title":"Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS","volume":"28","author":"Jabarpour","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e13717","DOI":"10.1111\/jfbc.13717","article-title":"Analysis of astaxanthin molecular targets based on network pharmacological strategies","volume":"45","author":"Lin","year":"2021","journal-title":"J. Food Biochem."},{"key":"ref_41","first-page":"225","article-title":"Cabergoline\u2019s Promise in Endometriosis: Restoring Molecular Balance to Improve Reproductive Potential","volume":"90","author":"Shahgholi","year":"2025","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103248","DOI":"10.1016\/j.jri.2020.103248","article-title":"A randomized exploratory trial to assess the effects of resveratrol on VEGF and TNF-\u03b1 expression in endometriosis women","volume":"143","author":"Khodarahmian","year":"2021","journal-title":"J. Reprod. Immunol."},{"key":"ref_43","first-page":"454","article-title":"Nonhormonal therapy for endometriosis: A randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate","volume":"2","author":"DiVasta","year":"2021","journal-title":"FS Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tejada, M.\u00c1., Santos-Llamas, A.I., Fern\u00e1ndez-Ram\u00edrez, M.J., Tar\u00edn, J.J., Cano, A., and G\u00f3mez, R. (2021). A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030269"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10863-020-09830-y","article-title":"Protective effect of cabergoline on mitochondrial oxidative stress-induced apoptosis is mediated by modulations of TRPM2 in neutrophils of patients with endometriosis","volume":"52","author":"Ekici","year":"2020","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Abramiuk, M., Grywalska, E., Ma\u0142kowska, P., Sierawska, O., Hrynkiewicz, R., and Nied\u017awiedzka-Rystwej, P. (2022). The Role of the Immune System in the Development of Endometriosis. Cells, 11.","DOI":"10.3390\/cells11132028"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kokot, I., Piwowar, A., J\u0119dryka, M., So\u0142kiewicz, K., and Kratz, E.M. (2021). Diagnostic Significance of Selected Serum Inflammatory Markers in Women with Advanced Endometriosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052295"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13298","DOI":"10.1111\/aji.13298","article-title":"Enhanced local and systemic inflammatory cytokine mRNA expression in women with endometriosis evokes compensatory adaptive regulatory mRNA response that mediates immune suppression and impairs cytotoxicity","volume":"84","author":"Vinnars","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bouquet de Joliniere, J., Fruscalzo, A., Khomsi, F., Stochino Loi, E., Cherbanyk, F., Ayoubi, J.M., and Feki, A. (2021). Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report. Front. Surg., 8.","DOI":"10.3389\/fsurg.2021.791686"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: A Masterplayer in the Cytokine Network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12026-020-09153-5","article-title":"Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis","volume":"68","author":"Mohamed","year":"2020","journal-title":"Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"gaab064","DOI":"10.1093\/molehr\/gaab064","article-title":"G-CSF and IL-6 may be involved in formation of endometriosis lesions by increasing the expression of angiogenic factors in neutrophils","volume":"27","author":"Guo","year":"2021","journal-title":"Mol. Hum. Reprod."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2147\/IJWH.S467041","article-title":"Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis","volume":"16","author":"Sullender","year":"2024","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/humrep\/deaa017","article-title":"Role of interleukin-1\u03b2 in nerve growth factor expression, neurogenesis and deep dyspareunia in endometriosis","volume":"35","author":"Peng","year":"2020","journal-title":"Hum. Reprod."},{"key":"ref_55","first-page":"47","article-title":"Interleukin-1\u03b2 and plasminogen activating system members in endometriotic stromal cell migration\/invasion","volume":"4","author":"Alotaibi","year":"2023","journal-title":"FS Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"gaac010","DOI":"10.1093\/molehr\/gaac010","article-title":"Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis","volume":"28","author":"Li","year":"2022","journal-title":"Mol. Hum. Reprod."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9803","DOI":"10.1038\/s41598-022-13764-3","article-title":"Role of CD47 in tumor immunity: A potential target for combination therapy","volume":"12","author":"Huang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_59","unstructured":"Hope Medicine (2025, October 26). A Study to Assess the Efficacy and Safety of HMI-115 in Subjects with Endometriosis-Associated Pain. ClinicalTrials.gov NCT05616208, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05616208."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ijgo.13677","article-title":"A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis","volume":"156","author":"Niakan","year":"2022","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijgo.14930","article-title":"Effects of Dienogest on breasts of women of reproductive age and women in menopausal transition: A cohort study","volume":"162","author":"Huang","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.fertnstert.2024.11.003","article-title":"Efficacy and safety of estetrol (15 mg)\/drospirenone (3 mg) combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: A multicenter, placebo-controlled, double-blind, randomized study","volume":"123","author":"Osuga","year":"2025","journal-title":"Fertil. Steril."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14656566.2023.2209315","article-title":"Aromatase inhibitors in the pharmacotherapy of endometriosis","volume":"24","author":"Gardella","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_64","first-page":"126","article-title":"The role of selected cytokines from the interleukin-1 family in the peritoneal fluid of women with endometriosis","volume":"96","author":"Wendlocha","year":"2024","journal-title":"Ginekol. Pol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103340","DOI":"10.1016\/j.jri.2021.103340","article-title":"The effects of Etanercept and cabergoline on endometriotic implants, uterus and ovaries in rat endometriosis model","volume":"146","author":"Vural","year":"2021","journal-title":"J. Reprod. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40814-021-00797-0","article-title":"Dichloroacetate as a possible treatment for endometriosis-associated pain: A single-arm open-label exploratory clinical trial (EPiC)","volume":"7","author":"Leow","year":"2021","journal-title":"Pilot Feasibility Stud."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"25389","DOI":"10.1073\/pnas.1916144116","article-title":"Repurposing dichloroacetate for the treatment of women with endometriosis","volume":"116","author":"Horne","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:24:44Z","timestamp":1790076284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":67,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187238"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187238","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}